Kate Rittenhouse-Olson (Past Speaker)

Kate Rittenhouse-Olson is founder, President and CSO of the biotechnology company For-Robin, Inc.  Her team is focused on ways to move hJAA-F11, a highly specific humanized antibody to TF-Ag, to the clinic for the cancer patient. In vivo data shows specificity and efficacy in human breast and lung cancer xenograft models.

Kate trained as a post-doctoral fellow at Roswell Park Cancer Institute (RPCI), wherein she gained clinical tumor immunology experience with T. Ming Chu, (the discoverer of Prostate Specific Antigen for diagnosis) and then carbohydrate experience with Khushi Matta. She taught clinical immunology for 24 years and has a Specialist in Immunology Certification from the ASCP.

She is a Professor emeritus and the founding Director of the Biotechnology undergraduate program at the University of Buffalo, recently stepping away from this position to focus on the clinical potential of hJAA-F11. She has also been editor of Immunological Investigations for the past 15 years and is co-author of the textbook “Contemporary Clinical Immunology and Serology”.